According to a recent report by Emergen Research, the market for non-invasive prenatal testing would reach USD 8.75 billion by 2027.
According to a recent report by Emergen Research, the market for non-invasive prenatal testing would reach USD 8.75 billion by 2027. Non-invasive prenatal testing (NIPT), sometimes referred to as cell-free DNA testing, is thought to provide a substantial advancement over existing diagnostic techniques for identifying foetal chromosome abnormalities. Additionally, NIPT is thought to be better to other screening methods, especially for trisomy 21 (one of the most prevalent congenital anomalies). With the help of NIPT, people can decide for themselves whether diagnostic testing is necessary. The genetic material that is present or absent in associated foetal chromosomal abnormalities can range from tiny portions of chromosomes to complete chromosomes.
Despite the fact that NIPT is accessible in an increasing number of places, a significant commercial push is anticipated to support customer expansion in the anticipated years. NIPT’s efficacy as a screening method with high sensitivity and specificity was proven by comparisons with conventional prenatal aneuploidy screening. Non-invasive prenatal testing is becoming more and more popular among expectant mothers as a viable alternative to amniocentesis and as a result of growing awareness of prenatal genetic issues.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/16
Non-invasive prenatal testing is anticipated to replace other, riskier screening techniques in the future as the frequency of pregnancy and its problems rises. NIPT performs screening faster than other prenatal screening methods and has an identification sensitivity of above 99 percent. Only a small number of players offer non-invasive pregnancy monitoring. Business expansion is constrained by the high cost of research and the interim diagnostic approach.
The development of NGS technology and cfDNA research has paved the road for the more accurate and less expensive detection of chromosomal abnormalities. The high-risk testing market is competitive, and further competition is probably going to cause significant drops in the retail sales price of such tests. Reduced prices in the reproductive genetics market can increase the prevalence of these research. The development of new NIPT technology is gradually expanding as more people become aware of the benefits of non-invasive procedures.
North America is anticipated to dominate the worldwide non-invasive prenatal testing market during the forecast period due to an increase in genetically defective deliveries, desire for cutting-edge screening techniques, and rising payer reimbursement for the associated risk during pregnancy. According to research done by the Health Expense Institute, the non-invasive pregnancy testing market in North America is anticipated to gain from the average USD 4,879.0 spent on children’s healthcare annually in the U.S. The Asia Pacific region is expected to experience significant growth in the global market for non-invasive prenatal research as a result of the growing emphasis on minimally invasive diagnostic procedures and preference for early detection of illness, as well as the recognition among citizens and expanding healthcare services.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/non-invasive-prenatal-testing-market
Further key findings from the report suggest
- According to the approach, ultrasound detection brought in USD 0.86 billion in revenue in 2019 and is anticipated to grow at a CAGR of 14.0 percent during the forecast period. This is because ultrasound diagnostic can find irregularities in the baby’s movements and position inside the womb.
- Due to the expanding adoption of non-invasive prenatal testing, quick technical advancements, and ground-breaking acceptance methods, the hospital segment is anticipated to rise with a CAGR of 14.1% during the projected period.
- The non-invasive prenatal testing market’s largest contributor is the trisomy application. Due to the high prevalence of genetic illnesses associated with trisomies, such as Patau syndrome, Down syndrome, and Edward syndrome, the trisomy application of the North American area is the largest shareholder of the market and owned around 45.1% of the market in 2019.
- Due to the availability of technologically cutting-edge healthcare research systems and the region’s manufacturing of WGS, North America dominated the market for non-invasive prenatal testing in 2019. In 2019, the North American region controlled over 48.8% of the market, while the European Union accounted for about 25.4%.
- Thermo Fisher Scientific Inc., GE Healthcare, PerkinElmer Inc., BGI, and Natera Inc. are a few notable participants. Yourgene Health, Illumina Inc., Agilent Technologies Inc., Laboratory Corporation of America Holdings, and F. Hoffmann-La Roche Ltd. are other significant players.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/16
For the purpose of this report, Emergen Research has segmented into the global Non-Invasive Prenatal Testing market based on the method, end-use, application, and region:
Method Outlook (Revenue, USD Billion; 2017-2027)
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-free DNA in Maternal Plasma Tests
- Others
End-Use Outlook (Revenue, USD Billion; 2017-2027)
- Diagnostic Laboratories
- Hospitals
- Research Centers
- Clinics
Application Outlook (Revenue, USD Billion; 2017-2027)
- Trisomy
- Microdeletion Syndrome
- Others
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Benelux
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- Rest of APAC
- MEA
- Saudi Arabia
- UAE
- Rest of MEA
- Latin America
- Brazil
- Rest of LATAM
Make an Inquiry Before Buying@ https://www.emergenresearch.com/purchase-enquiry/16
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-non-invasive-prenatal-testing-market